MedTrace Logo

Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients

NCT00818597 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-01-07

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of an extracorporeal application of a bed-side bioreactor containing human donor granulocytes on the course and outcome of septic shock in humans.

Conditions

  • Severe Sepsis and Septic Shock

Interventions

DEVICE

EISS

Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.

Sponsors & Collaborators

  • University of Rostock

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2004-04-30
Completion
2008-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818597 on ClinicalTrials.gov